Compare MSCI & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSCI | KVUE |
|---|---|---|
| Founded | 1998 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Specialty Chemicals |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6B | 39.9B |
| IPO Year | 2007 | 2023 |
| Metric | MSCI | KVUE |
|---|---|---|
| Price | $536.97 | $16.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $655.90 | $20.31 |
| AVG Volume (30 Days) | 619.7K | ★ 37.2M |
| Earning Date | 10-28-2025 | 11-03-2025 |
| Dividend Yield | 1.34% | ★ 4.90% |
| EPS Growth | 3.54 | ★ 35.31 |
| EPS | ★ 15.77 | 0.75 |
| Revenue | $3,055,440,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $11.86 | N/A |
| Revenue Next Year | $9.26 | $2.81 |
| P/E Ratio | $34.12 | ★ $22.64 |
| Revenue Growth | ★ 9.02 | N/A |
| 52 Week Low | $486.74 | $14.02 |
| 52 Week High | $642.45 | $25.17 |
| Indicator | MSCI | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 34.63 | 55.31 |
| Support Level | $556.06 | $16.75 |
| Resistance Level | $567.21 | $17.19 |
| Average True Range (ATR) | 10.65 | 0.42 |
| MACD | -3.24 | 0.03 |
| Stochastic Oscillator | 13.90 | 60.56 |
MSCI has described its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. MSCI boasts about $17 trillion in benchmarked assets, including over $2.2 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. In its sustainability and climate segment, MSCI provides ESG data to the investment industry. In private assets, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.